Advertisement
Advertisement
U.S. markets open in 9 hours 2 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Biotest Aktiengesellschaft (BIO.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
42.60+0.10 (+0.24%)
At close: 05:36PM CEST
Advertisement

Biotest Aktiengesellschaft

Landsteinerstrasse 5
Dreieich 63303
Germany
49 61 03 801 0
https://www.biotest.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees1,967

Key Executives

NameTitlePayExercisedYear Born
Dr. Michael RamrothChairman of the Management Board, CEO & CFO2.1MN/A1962
Dr. Georg FloßCOO & Member of the Board of Management1.17MN/AN/A
Dr. Jorg SchuttrumpfChief Scientific Officer & Member of the Management BoardN/AN/A1974
Dr. Monika ButtkereitHead of Investor RelationsN/AN/AN/A
Dr. Christina ErbHead of Corp. HRN/AN/AN/A
Dr. Katrin BernösterHead of the Project Management OrganisationN/AN/AN/A
Mr. Peter SeithHead of Quality OperationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.

Corporate Governance

Biotest Aktiengesellschaft’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement